Pharmacogenomics hub in a strengthened IMGGE (PharmGenHUB)
Апстракт
Adverse drug reactions kill hundreds of thousands of patients every year in Europe alone.
Hence the development of pharmacogenomics (PGX) to personalise therapies to improve the
outcomes of the treatments is of great importance. The EU-funded PharmGenHUB project will
support the effort of several university partners, coordinated by the Institute of Molecular
Genetics and Genetic Engineering at the University of Belgrade in Serbia to develop PGX
diagnostics, education, training, and translation of PGX knowledge into digital solutions for
medical applications in the Western Balkans (WB) region. The project will employ high-
throughput DNA sequencing to identify WB-specific drug-PGX marker pairs and to design
electronic tools for treatment individualisation in clinical practice.
Извор:
European Comission, 2022Финансирање / пројекти:
- European Comission, 101059870
Напомена:
- Principal Investigator: Dr Branka Zukic
- Duration period: 2022-2025
Колекције
Институција/група
Institut za molekularnu genetiku i genetičko inženjerstvoTY - GEN PY - 2022 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/2230 AB - Adverse drug reactions kill hundreds of thousands of patients every year in Europe alone. Hence the development of pharmacogenomics (PGX) to personalise therapies to improve the outcomes of the treatments is of great importance. The EU-funded PharmGenHUB project will support the effort of several university partners, coordinated by the Institute of Molecular Genetics and Genetic Engineering at the University of Belgrade in Serbia to develop PGX diagnostics, education, training, and translation of PGX knowledge into digital solutions for medical applications in the Western Balkans (WB) region. The project will employ high- throughput DNA sequencing to identify WB-specific drug-PGX marker pairs and to design electronic tools for treatment individualisation in clinical practice. T2 - European Comission T1 - Pharmacogenomics hub in a strengthened IMGGE (PharmGenHUB) UR - https://hdl.handle.net/21.15107/rcub_imagine_2230 ER -
@misc{ year = "2022", abstract = "Adverse drug reactions kill hundreds of thousands of patients every year in Europe alone. Hence the development of pharmacogenomics (PGX) to personalise therapies to improve the outcomes of the treatments is of great importance. The EU-funded PharmGenHUB project will support the effort of several university partners, coordinated by the Institute of Molecular Genetics and Genetic Engineering at the University of Belgrade in Serbia to develop PGX diagnostics, education, training, and translation of PGX knowledge into digital solutions for medical applications in the Western Balkans (WB) region. The project will employ high- throughput DNA sequencing to identify WB-specific drug-PGX marker pairs and to design electronic tools for treatment individualisation in clinical practice.", journal = "European Comission", title = "Pharmacogenomics hub in a strengthened IMGGE (PharmGenHUB)", url = "https://hdl.handle.net/21.15107/rcub_imagine_2230" }
(2022). Pharmacogenomics hub in a strengthened IMGGE (PharmGenHUB). in European Comission. https://hdl.handle.net/21.15107/rcub_imagine_2230
Pharmacogenomics hub in a strengthened IMGGE (PharmGenHUB). in European Comission. 2022;. https://hdl.handle.net/21.15107/rcub_imagine_2230 .
"Pharmacogenomics hub in a strengthened IMGGE (PharmGenHUB)" in European Comission (2022), https://hdl.handle.net/21.15107/rcub_imagine_2230 .